• Splash Beverage entered a development and collaboration deal with Lupvindol Biosciences on July 31, 2026, to advance CannEpil as an FDA-regulated veterinary drug.
• Lupvindol will lead FDA Center for Veterinary Medicine work, targeting an INAD process and conditional approval under Section 571.
• Agreement sets milestone funding of USD 1.11 million through conditional approval, including USD 500,000 at approval or an earlier licensing transaction.
• Lupvindol also earns a 4% net sales royalty for 10 years from first commercial sale, with an option to take common stock instead.
• Initial term is five years with auto-renewal; Splash can terminate for convenience with 90 days’ notice and a wind-down fee equal to the next milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Splash Beverage Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001012), on August 04, 2026, and is solely responsible for the information contained therein.